
Associate director of healthcare and public health programs at the Digital Medicine Society (DiMe), a global nonprofit and professional home for digital medicine

Associate director of healthcare and public health programs at the Digital Medicine Society (DiMe), a global nonprofit and professional home for digital medicine

Chief product and technology officer, Arcadia, a healthcare data company headquartered in Boston

Vice president of legal and compliance at Abarca Health, a pharmacy benefits manager and healthcare technology company.

Chief medical officer, complex care, AbsoluteCare, an integrated healthcare provider headquartered in Columbia, Maryland

Health Equity Officer at UCare, an independent, nonprofit health plan company with members in Minnesota and western Wisconsin

Director, specialty clinical solutions, Prime Therapeutics LLC, a pharmacy benefits manager in Eagan, Minnesota

Director, specialty pharmacy, Horizon Blue Cross Blue Shield of New Jersey

Vice president of implementation and sales, Longevity Health, a clinical services company and institutional special needs plan (ISNP) for nursing home residents

Executive director, specialty digital and patient innovation, CVS Health

Population health analyst on a dedicated health equity team, Optum Rx

Co-founder and CEO at Fabric Health, a public benefit corporation that conducts outreach about health benefits at laundromats

Director, formulary operations, Capital Rx, a pharmacy benefits manager and healthcare technology company

General counsel, 1upHealth, Inc., a healthcare data interoperability company in Boston.

Health equity program director, Fallon Health, a not-for-profit health plan and provider of care headquartered in Worcester, Massachusetts.

Incorporating hospice care into Medicare Advantage didn’t work out, and CMS is looking to identify low-quality providers.

As the understanding of atopic dermatitis has improved, treatment options have increased. One unresolved issue is when and if to start systemic therapy in young children.


If approved by the FDA they would join Trodelvy as a treatment for triple-negative breast cancer.